% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@MISC{Lohmann:908215,
author = {Lohmann, Philipp and Meissner, Anna-Katharina and Werner,
Jan-Michael and Stoffels, Gabriele and Kocher, Martin and
Bauer, Elena and Fink, Gereon and Shah, Nadim and Langen,
Karl-Josef and Galldiks, Norbert},
title = {{NIMG}-38. {NON}-{INVASIVE} {PREDICTION} {OF} {MGMT}
{PROMOTER} {METHYLATION} {USING} {COMBINED} {FET}
{PET}/{MRI} {RADIOMICS}},
reportid = {FZJ-2022-02466},
year = {2020},
abstract = {BACKGROUNDRecently, the Response Assessment in
Neuro-Oncology (RANO) Working Group emphasized the
additional diagnostic value of amino acid PET in addition to
MRI. However, the number of studies using amino acid PET/MRI
radiomics is still low. We investigated the potential of
combined O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET/MRI
radiomics for the non-invasive prediction of the
O6-methylguanine-DNA methyl-transferase (MGMT) promoter
methylation status in glioma patients.METHODSSeventy-one
patients with newly diagnosed glioma (predominantly WHO
grade III and IV glioma, $82\%)$ underwent a hybrid FET
PET/MRI scan. Forty-six patients $(65\%)$ had a methylated
MGMT promoter. The tumor and tumor subregions were manually
segmented on conventional MRI. In total, 199 standardized
features were obtained from FET PET, contrast-enhanced
T1-weighted, T2-weighted, and fluid attenuated inversion
recovery (FLAIR) MRI. After feature extraction and data
normalization, patients were randomly assigned to a training
and a test dataset for final model evaluation in a ratio of
70/30, with a balanced distribution of the MGMT promoter
methylation status. Feature selection was performed by
recursive feature elimination using random forest
regressors. For the final model generation, the number of
features was limited to seven to avoid data overfitting.
Different algorithms for model generation were compared, and
the model performance in the training data was assessed by
5-fold cross-validation. Finally, the best performing models
were applied to the test dataset to evaluate the robustness
of the models.RESULTSIn the test dataset, the best radiomics
signatures obtained from MRI or FET PET alone achieved
diagnostic accuracies for the prediction of the MGMT
promoter methylation of $64\%$ and $70\%,$ respectively. In
contrast, the highest diagnostic accuracy of $83\%$ was
obtained by combining FET PET and MRI
features.CONCLUSIONCombined FET PET/MRI radiomics allows the
non-invasive prediction of the MGMT promoter methylation
status in patients with gliomas, providing more diagnostic
information than either modality alone.},
cin = {INM-11 / INM-4 / JARA-BRAIN / INM-3},
ddc = {610},
cid = {I:(DE-Juel1)INM-11-20170113 / I:(DE-Juel1)INM-4-20090406 /
I:(DE-Juel1)VDB1046 / I:(DE-Juel1)INM-3-20090406},
pnm = {5253 - Neuroimaging (POF4-525)},
pid = {G:(DE-HGF)POF4-5253},
typ = {PUB:(DE-HGF)4},
url = {https://juser.fz-juelich.de/record/908215},
}